Clostridium difficile toxin A therapy for HCT 116 human colon cancer in nude mice.
Clostridium difficile toxin A was evaluated for an antitumor effect in vivo on HCT 116 human colon carcinoma cells growing subcutaneously in nude mice. A mean reduction in tumor volume of at least 65%, by measurement in three dimensions, was observed in mice who received two 9- to 13-day courses of daily intraperitoneal injections of toxin A as compared to mice receiving diluent alone. Reversible adverse effects of toxin A were noted in some animals, consisting primarily of liver toxicity and skin rash. HCT 116 cells in toxin A-treated mice grew as flattened tumors with ulcerated centers compared to rounded tumors without ulceration in controls. Histologic examination of tumors from representative mice revealed that two thirds of the tumor in a treated mouse was necrotic compared to only one third in a control, suggesting greater antitumor efficacy of toxin A than estimated by tumor measurements alone.
Department of Microbiology, Medical College of Wisconsin, Milwaukee.
P N
PN
Redlich
V M
VM
Kushnaryov
I
I
Hernandez
S E
SE
Grossberg
D000818:Animals; D001427:Bacterial Toxins; D016360:Clostridioides difficile; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004768:Enterotoxins / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D014407:Tumor Cells, Cultured
D001427:Bacterial Toxins; D004768:Enterotoxins; C041348:tcdA protein, Clostridium difficile